All Posts
Cross sectional-study | Higher beverage fructose intake linked to adverse profiles on multiple cardiometabolic biomarkers
17 Jan, 2023 | 13:17h | UTCCommentary: Beverage fructose intake may lead to an abnormal cardiometabolic profile – News Medical
A before-and-after evaluation of a national quality improvement program to increase the uptake of magnesium sulfate in preterm deliveries
17 Jan, 2023 | 13:14h | UTCNews Release: Study finds program to prevent cerebral palsy in premature babies is effective – University of Bristol
Podcast | Adrenal incidentalomas
17 Jan, 2023 | 13:16h | UTC#377 Adrenal Incidentalomas with Dr. William Young – The Curbsiders
Glomerulonephritis: immunopathogenesis and immunotherapy
17 Jan, 2023 | 13:12h | UTCGlomerulonephritis: immunopathogenesis and immunotherapy – Nature Reviews Immunology (if the link is paywalled, try this one)
Commentary on Twitter
A Review in @NatRevImmunol proposes a new grouping of glomerulonephritis disorders based on their underlying immunopathogenesis, with a view to improving diagnosis, mechanistic understanding and treatment of these immune-mediated kidney diseases. https://t.co/5EsGFBpU3K pic.twitter.com/KULbWS0xMz
— Nature Portfolio (@NaturePortfolio) January 15, 2023
RCT | Ultrasound-guided percutaneous cryoneurolysis to treat chronic postamputation phantom limb pain
17 Jan, 2023 | 13:13h | UTC
RCT | Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after auto-SCT in patients with multiple myeloma
17 Jan, 2023 | 13:11h | UTCCarfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
News Release: Triple-drug therapy for post-transplant management of multiple myeloma – University of Chicago Medical Center
RCT | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy
17 Jan, 2023 | 13:10h | UTCInvited commentary: Treatment withdrawal in Crohn’s disease: slowly becoming clearer – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary on Twitter
New research – Louis et al – Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialhttps://t.co/T40BmgHtem#IBD #GITwitter #medtwitter pic.twitter.com/iOIbi0WowU
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 12, 2023
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments
17 Jan, 2023 | 13:08h | UTC
Commentary on Twitter
Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments https://t.co/LCV8X0t4CZ @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/InOj7mDts7
— European Society of Cardiology Journals (@ESC_Journals) January 16, 2023
M-A | Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival?
17 Jan, 2023 | 13:07h | UTC
RCT | Effective dose of ephedrine for treatment of hypotension after induction of anesthesia in neonates and infants less than 6 months of age
17 Jan, 2023 | 13:06h | UTCEffective dose of ephedrine for treatment of hypotension after induction of general anaesthesia in neonates and infants less than 6 months of age: a multicentre randomised, controlled, open label, dose escalation trial – British Journal of Anaesthesia (link to abstract – $ for full-text)
RCT | Effect of 5% EMLA cream on postoperative sore throat in adults following general endotracheal anesthesia
17 Jan, 2023 | 13:05h | UTCEffect of 5% EMLA Cream on Postoperative Sore Throat in Adults Following General Endotracheal Anesthesia: A Randomized Placebo-Controlled Study – Anesthesia & Analgesia (link to abstract – $ for full-text)
Review | Difficult diagnosis in the ICU: making the right call but beware uncertainty and bias
17 Jan, 2023 | 13:02h | UTCDifficult diagnosis in the ICU: making the right call but beware uncertainty and bias – Anaesthesia
Review | Viral infections in critical care
17 Jan, 2023 | 13:01h | UTCViral infections in critical care: a narrative review – Anaesthesia
M-A | Efficacy and safety of corticosteroids in cardiac arrest
17 Jan, 2023 | 13:03h | UTC
Review | Current perspectives on maternity critical care
17 Jan, 2023 | 13:00h | UTCCurrent perspectives on maternity critical care – Anaesthesia
Review | Liver intensive care for the general intensivist
17 Jan, 2023 | 12:59h | UTCLiver intensive care for the general intensivist – Anaesthesia
Establishment and external validation of neutrophil-to-lymphocyte ratio in excluding postoperative pancreatic fistula after pancreatoduodenectomy
17 Jan, 2023 | 12:57h | UTC
M-A | Colonisation with ESCR-Enterobacterales and infection risk in surgical patients
17 Jan, 2023 | 12:58h | UTC
2023 ASA Guidelines for preoperative fasting
15 Jan, 2023 | 20:42h | UTC
WHO updates COVID-19 guidelines on masks, treatments and patient care
15 Jan, 2023 | 20:44h | UTCWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
WHO Updated Guidelines:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Cohort Study | Adverse events identified in nearly one in four hospital admissions
15 Jan, 2023 | 20:40h | UTCThe Safety of Inpatient Health Care – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Nearly 1 in 4 Hospital Patients Have Harmful Event During Their Stay – HealthDay
Commentary on Twitter
A retrospective cohort study assessed patient safety in 11 Massachusetts hospitals in 2018. Adverse events were identified in 24% of hospital admissions and preventable adverse events in 7%. https://t.co/o4JM4JbxSF pic.twitter.com/yPSnvXM5IR
— NEJM (@NEJM) January 13, 2023
Review | Long COVID: major findings, mechanisms and recommendations
15 Jan, 2023 | 20:34h | UTCLong COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
15 Jan, 2023 | 20:33h | UTCA survey of COVID-19 vaccine acceptance across 23 countries in 2022 – Nature Medicine
News Release: Global COVID-19 vaccine acceptance rising but hesitancy remains – London School of Hygiene & Tropical Medicine
Commentary on Twitter
The third annual iteration of a survey assessing vaccine confidence in 23 countries shows the overall willingness to accept a COVID-19 vaccine has increased, although results were heteregeous across countries, according to a @NatureMedicine paper. https://t.co/0EkMH7oRdn pic.twitter.com/bLc98F9AYt
— Nature Portfolio (@NaturePortfolio) January 13, 2023
RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19
15 Jan, 2023 | 20:37h | UTCEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Commentary on Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Best infectious diseases articles from 2022 – A year end review of non-COVID literature
15 Jan, 2023 | 20:31h | UTC
Commentary on Twitter
🔥🔥NEW 🔥🔥
Our new post, a great collaboration w 🌟 @IDstewardship
Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
1️⃣7️⃣⚡️🆔 RCTs @NEJM @TheLancet ✨
2️⃣syst Rev
3️⃣🌏Guidelines @Wiki_Guidelines
#IDTwitter #TwitteRxhttps://t.co/JL07NLa3BV pic.twitter.com/Qcf2cwK8Sd— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) January 4, 2023